Interventions for Neuropathic Pain: An Overview of Systematic Reviews

Došenović, Svjetlana; Kadić, Antonia Jeličić; Miljanović, Maja; Biočić, Mihovil; Borić, Krste; Ćavar, Marija; Markovina, Nikolina; Vučić, Katarina; Puljak, Livia

doi:10.1213/ane.0000000000001998

Cited by 80 publications

(22 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the evidence for these interventions is often inconclusive. 2 In addition, side effects associated with the medications such as dizziness, ataxia, nausea, vomiting, somnolence, and rash can be troublesome and debilitating. 3 …”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Meng¹,

Peng²,

Yang³

et al. 2018

JPR

View full text Add to dashboard Cite

AimThis meta-analysis was performed to evaluate the efficacy and safety of botulinum toxin-A (BTX-A) for the treatment of neuralgia.MethodsWe searched PubMed, EMBASE, and Cochrane databases to identify randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain. Primary outcome measures were pain scores up to 24 weeks after treatment. Secondary outcomes were hours of sleep, Short Form-36 (SF-36) life quality questionnaire, and adverse events. We used Review Manager 5.3 for the data analyses.ResultsTwelve RCTs were included (n=495). Pain scores in the BTX-A group were significantly lower compared to the saline group at 4 weeks (mean difference [MD] =−1.64, 95% CI [−3.21, −0.07], P=0.04), 12 weeks (MD =−1.49, 95% CI [−2.05, −0.93], P<0.00001), and 24 weeks (MD =−1.61, 95% CI [−2.81, −0.40], P=0.009). There were no significant differences in hours of sleep, SF-36 questionnaire, or the incidence of injection pain or hematoma between the two groups. No serious adverse events associated with BTX-A were noted. Fourteen out of 108 patients (12.9%) with trigeminal neuralgia experienced mild facial asymmetry after the BTX-A treatment.ConclusionBased on the current evidence, BTX-A may be an effective and safe option for the treatment of neuralgia. Due to the limited number of patients included in this meta-analysis, more trials are still needed to confirm these results.

show abstract

Section: Introductionmentioning

confidence: 99%

Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Meng¹,

Peng²,

Yang³

et al. 2018

JPR

View full text Add to dashboard Cite

show abstract

“…NP is a chronic, highly disabling condition caused by a lesion or disease of the somatosensory nervous system which affects from 1.5 to 6.9% of individuals aged 50–64 years ( 10 , 11 ).…”

Section: Discussionmentioning

confidence: 99%

“…Current pharmacological and non-pharmacological treatment of NP is still unsatisfactory ( 9 , 11 , 12 ). Besides lidocaine, capsaicin, antidepressants, anticonvulsants, and opioids, botulinum toxin (BoNT) has more recently emerged as a promising NP therapeutic strategy ( 13 , 14 ).…”

Section: Introductionmentioning

confidence: 99%

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

2020

View full text Add to dashboard Cite

Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders. This review summarizes the evidence from the published literature regarding its effect on neuropathic pain. Almost all investigations were performed using onabotulinum toxin type A (BoNT/A). Most studies provided positive results, even though toxin formulation, dose, dilution, injection techniques, and sites are heterogeneous across studies. Future larger, high-quality, specifically designed clinical trials are warranted to confirm botulinum neurotoxin efficacy in neuropathic pain.

show abstract

“…Despite a high prevalence rate, the pathological mechanism of DN remains unknown. [2,3] Early detection of DN can only be achieved by assessing the nerve fibers, and current treatment of DN is limited to certain non-specific drugs with side effects and possibility of abuse. [1,4] DN has a significant impact on the health-related quality of life.…”

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation relieve painful diabetic neuropathy

Cai

Yong

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Fecal microbiota transplantation (FMT) has been used in a wide variety of diseases. In this article, we reported a 46-year-old female with diabetic neuropathy (DN) achieved remission by the treatment of FMT.Patient concerns:The patient with an 8-year history of diabetes and hypertension was admitted to hospital due to sensitive pain of her right thigh and poor blood glucose control. The traditional hypoglycemic and analgesic treatment were useless to her symptoms.Diagnosis:Diabetic-induced neuropathy was considered.Interventions:This patient received twice FMTs for 3 months.Outcomes:After twice FMTs, the clinical response of patient was pleasant. The glycemic control was improved, with a remarkable relief of the symptoms of painful DN in particular. No obvious adverse effects were observed during the FMTs and follow-up observation-testing.Lessons:We proposed that FMT could be a promising treatment in patients with diabetes or diabetes-related complications like DN. FMT also appeared to be definitely safer and more tolerable than the pharmacologic treatment in patients with DN.

show abstract

Interventions for Neuropathic Pain: An Overview of Systematic Reviews

Cited by 80 publications

References 72 publications

Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

Fecal microbiota transplantation relieve painful diabetic neuropathy

Contact Info

Product

Resources

About